According to the China Ulcerative Colitis Market, by Drug Therapy (5-Aminosalicylates {Mesalazine, Balsalazide, Olsalazine, and Others}, Monoclonal Antibodies {Vedolizumab, Adalimumab, Infliximab, Golimumab, and Ustekinumab}, Steroids {Budesonide, Prednisone, Beclomethasone, Deflazacort, and Others}, Antibiotics, Late Stage Pipeline Molecules {Zeposia, Etrasimod and Others}, and Other Drugs), by Dosage Form (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is estimated to be valued at US$ 190.2 million in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030).
Market players are indulged in launching new products for the treatment of ulcerative colitis and this is expected to drive the growth of the China ulcerative colitis market, over the forecast period. for instance, in July 2021, Tillotts Pharma AG, a part of the Zeria Group, announced the launch of Asacol 800 mg tablets (mesalazine) as first-line treatment for mild to moderate ulcerative colitis (UC) in the People’s Republic of China, after announcing the successful partnership of Tillotts Pharma AG and Menarini, an Italy-based pharmaceutical company, in October 2019.
Key players are focusing on conducting research and development activities, for the innovation of new products for the treatment of ulcerative colitis, this is expected to increase the growth of the China ulcerative colitis market. For instance, in November 2021, InDex Pharmaceuticals Holding AB announced that the first patient has been enrolled in the pivotal phase III study CONCLUDE (Cobitolimod Novel Concept for Left-sided Ulcerative Colitis Disease Evaluation Study). The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
China Ulcerative Colitis Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the China ulcerative colitis market. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. Thus, impact of the Coronavirus (COVID-19) pandemic is expected to limit the growth of the China ulcerative colitis market during the forecast period, owing to increasing risk of severe COVID-19 due to medications of inflammatory bowel disease (IBD).
For instance, according to article published in March 2021, in British Medical Journal, based on data from Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) a large, international registry, over 1400 patients with IBD from 47 countries using thiopurine monotherapy and the combination of thiopurines with tumor necrosis factor (TNF) antagonists were found to be associated with a significantly increased risk of severe COVID-19.
Browse 49 Market Data Tables and 35 Figures spread through 408 Pages and in-depth TOC on China Ulcerative Colitis Market, by Drug Therapy (5-Aminosalicylates {Mesalazine, Balsalazide, Olsalazine, and Others}, Monoclonal Antibodies {Vedolizumab, Adalimumab, Infliximab, Golimumab, and Ustekinumab}, Steroids {Budesonide, Prednisone, Beclomethasone, Deflazacort, and Others}, Antibiotics, Late Stage Pipeline Molecules {Zeposia, Etrasimod, and Others}, and Other Drugs), by Dosage Form (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
To know the latest trends and insights prevalent in the ulcerative colitis market, click the link below:
https://www.coherentmarketinsights.com/market-insight/china-ulcerative-colitis-market-4862
There has been increase in the number of signing agreements by the market players, this is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in February 2018, Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, announced that it has entered into a global co-development and commercialization agreement for TD-1473 and related back-up compounds for inflammatory intestinal diseases such as ulcerative colitis and Crohn's disease with Janssen Biotech, Inc., one of Johnson & Johnson's pharmaceutical companies.
Key Takeaways of the Ulcerative Colitis Market:
- The China ulcerative colitis market is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030), owing to growth in potential markets in China
- Market players are indulged in inorganic activities, such as collaboration and this is expected to increase the growth of the China ulcerative colitis market, over the forecast period. For instance, in December 2017, Boehringer Ingelheim and Roche announced a collaboration aimed at discovering and developing orally accessible new Locked Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel disorders (IBDs). Boehringer Ingelheim and Roche will collaborate to deliver new therapy options to IBD patients by combining their complementary expertise and cutting-edge LNA technology.
- Some of the major players operating in the China ulcerative colitis market include AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED
